Impact of the COVID-19 Pandemic on Pulmonary Hypertension Patients: Insights from the BNP-PL National Database.

Autor: Mamzer A; 1st Department of Cardiology, Bieganski Hospital, Medical University of Lodz, ul. Kniaziewicza 1/5, 91-347 Lodz, Poland., Waligora M; Pulmonary Circulation Centre, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital in Krakowul, Pradnicka 80, 31-202 Krakow, Poland., Kopec G; Pulmonary Circulation Centre, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital in Krakowul, Pradnicka 80, 31-202 Krakow, Poland., Ptaszynska-Kopczynska K; Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland., Kurzyna M; Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, 05-400 Otwock, Poland., Darocha S; Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, 05-400 Otwock, Poland., Florczyk M; Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, 05-400 Otwock, Poland., Mroczek E; Institute of Heart Diseases, University Clinical Hospital Mikulicz Radecki in Wroclaw, ul. Borowska 213, 50-558 Wroclaw, Poland., Mularek-Kubzdela T; Department of Cardiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland., Smukowska-Gorynia A; Department of Cardiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland., Wrotynski M; Department of Cardiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland., Chrzanowski L; 1st Department of Cardiology, Bieganski Hospital, Medical University of Lodz, ul. Kniaziewicza 1/5, 91-347 Lodz, Poland., Dzikowska-Diduch O; Department of Internal Medicine and Cardiology, Medical University of Warsaw, 02-005 Warsaw, Poland., Perzanowska-Brzeszkiewicz K; Department of Internal Medicine and Cardiology, Medical University of Warsaw, 02-005 Warsaw, Poland., Pruszczyk P; Department of Internal Medicine and Cardiology, Medical University of Warsaw, 02-005 Warsaw, Poland., Skoczylas I; 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland., Lewicka E; Department of Cardiology and Electrotherapy, Medical University of Gdansk, 80-211 Gdansk, Poland., Blaszczak P; Department of Cardiology, Cardinal Wyszynski Hospital, 20-718 Lublin, Poland., Karasek D; 2nd Department of Cardiology, Faculty of Health Sciences, Collegium Medicum, Nicolaus Copernicus University, 85-168 Bydgoszcz, Poland., Kusmierczyk-Droszcz B; Department of Congenital Heart Disease, Institute of Cardiology, 04-628 Warsaw, Poland., Mizia-Stec K; 1st Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 41-800 Katowice, Poland., Kaminski K; Department of Population Medicine and Civilization Diseases Prevention, Medical University of Bialystok, 15-269 Bialystok, Poland., Jachec W; 2nd Department of Cardiology, School of Medicine with Dentistry Division in Zabrze, Medical University of Silesia in Katowice, 41-800 Zabrze, Poland., Peregud-Pogorzelska M; Department of Cardiology, Pomeranian Medical University, 70-111 Szczecin, Poland., Doboszynska A; Pulmonary Department, University of Warmia and Mazury, 10-357 Olsztyn, Poland., Gasior Z; Department of Cardiology, School of Health Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland., Tomaszewski M; Department of Cardiology, Medical University of Lublin, 20-090 Lublin, Poland., Pawlak A; Department of Invasive Cardiology, Polish Academy of Sciences, Mossakowski Medical Research Centre, Central Clinical Hospital of the Ministry of Interior, 02-507 Warsaw, Poland., Zablocka W; Department of Invasive Cardiology and Cardiology, Independent Public Provincial Complex Hospital in Szczecin, 71-455 Szczecin, Poland., Ryczek R; Department of Cardiology and Internal Medicine, Military Institute of Medicine in Warsaw, 04-141 Warsaw, Poland., Widejko-Pietkiewicz K; Department of Cardiology, Copper Health Center, 59-300 Lubin, Poland., Kasprzak JD; 1st Department of Cardiology, Bieganski Hospital, Medical University of Lodz, ul. Kniaziewicza 1/5, 91-347 Lodz, Poland.
Jazyk: angličtina
Zdroj: International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Jul 10; Vol. 19 (14). Date of Electronic Publication: 2022 Jul 10.
DOI: 10.3390/ijerph19148423
Abstrakt: We aimed to evaluate the clinical course and impact of the SARS-CoV-2 pandemic on the rate of diagnosis and therapy in the complete Polish population of patients (pts) with pulmonary arterial hypertension (PAH-1134) and CTEPH (570 pts) treated within the National Health Fund program and reported in the national BNP-PL database. Updated records of 1704 BNP-PL pts collected between March and December 2020 were analyzed with regard to incidence, clinical course and mortality associated with COVID-19. Clinical characteristics of the infected pts and COVID-19 decedents were analyzed. The rates of new diagnoses and treatment intensification in this period were studied and collated to the proper intervals of the previous year. The incidence of COVID-19 was 3.8% (n = 65) (PAH, 4.1%; CTEPH, 3.2%). COVID-19-related mortality was 28% (18/65 pts). Those who died were substantially older and had a more advanced functional WHO class and more cardiovascular comorbidities (comorbidity score, 4.0 ± 2.1 vs. 2.7 ± 1.8; p = 0.01). During the pandemic, annualized new diagnoses of PH diminished by 25-30% as compared to 2019. A relevant increase in total mortality was also observed among the PH pts (9.7% vs. 5.9% pre-pandemic, p = 0.006), whereas escalation of specific PAH/CTEPH therapies occurred less frequently (14.7% vs. 21.6% pre-pandemic). The COVID-19 pandemic has affected the diagnosis and treatment of PH by decreasing the number of new diagnoses, escalating therapy and enhancing overall mortality. Pulmonary hypertension is a risk factor for worsened course of COVID-19 and elevated mortality.
Databáze: MEDLINE
Externí odkaz: